Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$5.39
-0.14 (-2.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $308.4M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
49.0x
↑EV/EBITDA
14.6x
↑ROE
5.3%
↑Gross Margin
28.0%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-10.6%
FCF CAGR
+11.6%
FCF margin
22.8%
FCF / Net income
4.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.48B · net income $82.9M · FCF $338.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.48B | $1.48B | $2.06B | $2.19B | $2.08B |
| Net Income | $82.9M | $82.9M | $138.0M | $44.4M | $55.6M |
| EBITDA | $159.5M | $159.5M | $229.3M | $132.4M | $137.0M |
| EPS | 0.14 | 0.14 | 0.23 | 0.07 | 0.09 |
| Gross Margin | 28.0% | 28.0% | 26.8% | 32.5% | 37.2% |
| Operating Margin | 10.7% | 10.7% | 10.0% | 4.5% | 4.6% |
| Net Margin | 5.6% | 5.6% | 6.7% | 2.0% | 2.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.04 | 0.06 | 0.14 |
| Current Ratio | 4.71 | 4.71 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $338.5M | $338.5M | $308.4M | $58.6M | $243.6M |
| Returns | |||||
| ROE | 5.3% | 5.3% | 9.1% | 3.1% | 4.0% |
| Valuation | |||||
| P/E | 49.00 | 49.00 | 25.27 | 90.86 | 79.96 |
| EV/EBITDA | 14.58 | 14.58 | 12.79 | 27.61 | 29.21 |
| P/B | 2.06 | 2.06 | 2.30 | 2.83 | 3.22 |
| Growth & Yield | |||||
| Revenue Growth | -28.0% | -28.0% | -6.1% | 5.6% | — |
| EPS Growth | -39.9% | -39.9% | 211.2% | -20.3% | — |
| Dividend Yield | 4.1% | 4.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
50.9%
EPS terminal req.
$0.48
Spread vs growth
-90.8%
5Y implied EPS CAGR
33.0%
EPS terminal req.
$0.58
Spread vs growth
-72.9%
10Y implied EPS CAGR
21.0%
EPS terminal req.
$0.93
Spread vs growth
-60.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.2%
Start / end P/E
25.4x → 38.7x
EPS bridge
0.23 → 0.14
Residual
-21.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.